Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have acute respiratory distress syndrome (ARDS). The new drug is expected to reduce the time which a patient need to be on the ventilator and improve patient\'s chances of survival. Currently there are no approved drugs for treating moderate or severe ARDS patients.
Epistemonikos ID: db3fa88982b2fabcda48bf51dfea45d92ce18292
First added on: Oct 23, 2021